SPHK2 and hepatocellular carcinoma: Transfection of SphK2 siRNA into HCC cells enhanced the inhibitory effect of regorafenib on the viability of regorafenib-resistant cells (Figure 4B), as the IC50 values of SphK2-knockdown regorafenib-resistant cells were lower than those of control group cells (Table 5).